SG11202110400QA - Fusion protein and use thereof - Google Patents
Fusion protein and use thereofInfo
- Publication number
- SG11202110400QA SG11202110400QA SG11202110400QA SG11202110400QA SG11202110400QA SG 11202110400Q A SG11202110400Q A SG 11202110400QA SG 11202110400Q A SG11202110400Q A SG 11202110400QA SG 11202110400Q A SG11202110400Q A SG 11202110400QA SG 11202110400Q A SG11202110400Q A SG 11202110400QA
- Authority
- SG
- Singapore
- Prior art keywords
- fusion protein
- fusion
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910260447.5A CN111763261B (en) | 2019-04-02 | 2019-04-02 | Fusion protein and application thereof |
PCT/CN2020/082861 WO2020200256A1 (en) | 2019-04-02 | 2020-04-01 | Fusion protein and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202110400QA true SG11202110400QA (en) | 2021-10-28 |
Family
ID=72664537
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202110400QA SG11202110400QA (en) | 2019-04-02 | 2020-04-01 | Fusion protein and use thereof |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220251154A1 (en) |
EP (1) | EP3950720A4 (en) |
JP (1) | JP2022527705A (en) |
KR (1) | KR20210146916A (en) |
CN (2) | CN111763261B (en) |
AU (1) | AU2020250613A1 (en) |
BR (1) | BR112021019570A2 (en) |
CA (1) | CA3131075A1 (en) |
SG (1) | SG11202110400QA (en) |
WO (1) | WO2020200256A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112023016717A2 (en) * | 2021-02-19 | 2023-10-31 | Seoul Nat Univ R&Db Foundation | BIESPECIFIC ANTIBODY THAT BINDS BIESPECIFICALLY TO PROGRAMMED DEATH LIGAND 1 AND DIFFERENTIATION CLUSTER 47, NUCLEIC ACID MOLECULE, AND, USE OF THE BIESPECIFIC ANTIBODY THAT BIESPECIFICALLY BINDS TO PROGRAMMED DEATH LIGAND 1 AND DIFFERENTIATION CLUSTER 47 |
CN113773401B (en) * | 2021-09-15 | 2023-06-20 | 宜明昂科生物医药技术(上海)股份有限公司 | Recombinant fusion protein targeting CD47 and PD-L1 and preparation and application thereof |
WO2023072279A1 (en) * | 2021-11-01 | 2023-05-04 | 江苏先声药业有限公司 | Sirpa mutant and application thereof |
CN116178561A (en) * | 2021-11-26 | 2023-05-30 | 杭州尚健生物技术有限公司 | Fusion proteins comprising SIRPalpha mutants |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
GB8822228D0 (en) | 1988-09-21 | 1988-10-26 | Southern E M | Support-bound oligonucleotides |
BRPI0811908A2 (en) * | 2007-05-25 | 2014-11-18 | Novartis Ag | STREPTOCOCCUS PNEUMONIAE PILUS ANTIGENS |
ES2567276T3 (en) * | 2011-05-12 | 2016-04-21 | Genentech, Inc. | LC-MS / MS method of monitoring multiple reactions to detect therapeutic antibodies in animal samples using frame-changing peptides |
WO2016022971A1 (en) * | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Sirp alpha-antibody fusion proteins |
TWI702228B (en) * | 2014-08-08 | 2020-08-21 | 美商Alx腫瘤技術股份有限公司 | Sirp-alpha variant constructs and uses thereof |
EP3643727A1 (en) * | 2014-08-15 | 2020-04-29 | Merck Patent GmbH | Sirp-alpha immunoglobulin fusion proteins |
RS62151B1 (en) * | 2015-08-07 | 2021-08-31 | Alx Oncology Inc | Constructs having a sirp-alpha domain or variant thereof |
JP2018526989A (en) * | 2015-08-07 | 2018-09-20 | ピエリス ファーマシューティカルズ ゲーエムベーハー | Novel fusion polypeptide specific for LAG-3 and PD-1 |
CN107459578B (en) * | 2016-05-31 | 2021-11-26 | 泰州迈博太科药业有限公司 | Difunctional fusion protein targeting CD47 and PD-L1 |
CN106967172B (en) * | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | The anti-PD-1 bifunctional antibody of anti-CTLA 4-, its medical composition and its use |
CN110325549B (en) * | 2016-12-09 | 2024-03-08 | 艾利妥 | anti-SIRP alpha antibodies and methods of use thereof |
CN113831417A (en) * | 2017-05-08 | 2021-12-24 | 上海津曼特生物科技有限公司 | Bispecific recombinant protein and application thereof |
CN109517054B (en) * | 2018-12-04 | 2022-04-08 | 江苏东抗生物医药科技有限公司 | SIRP alpha variant or fusion protein thereof and application thereof |
CN109535263B (en) * | 2018-12-04 | 2022-06-17 | 江苏东抗生物医药科技有限公司 | SIRP alpha mutant and fusion protein thereof |
-
2019
- 2019-04-02 CN CN201910260447.5A patent/CN111763261B/en active Active
-
2020
- 2020-04-01 WO PCT/CN2020/082861 patent/WO2020200256A1/en unknown
- 2020-04-01 US US17/599,733 patent/US20220251154A1/en active Pending
- 2020-04-01 BR BR112021019570A patent/BR112021019570A2/en unknown
- 2020-04-01 EP EP20782966.4A patent/EP3950720A4/en active Pending
- 2020-04-01 AU AU2020250613A patent/AU2020250613A1/en not_active Abandoned
- 2020-04-01 CA CA3131075A patent/CA3131075A1/en active Pending
- 2020-04-01 KR KR1020217030645A patent/KR20210146916A/en not_active Application Discontinuation
- 2020-04-01 SG SG11202110400QA patent/SG11202110400QA/en unknown
- 2020-04-01 CN CN202080023723.7A patent/CN113631582A/en active Pending
- 2020-04-01 JP JP2021556959A patent/JP2022527705A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN111763261B (en) | 2022-08-09 |
CN111763261A (en) | 2020-10-13 |
JP2022527705A (en) | 2022-06-03 |
BR112021019570A2 (en) | 2021-11-30 |
KR20210146916A (en) | 2021-12-06 |
US20220251154A1 (en) | 2022-08-11 |
EP3950720A1 (en) | 2022-02-09 |
AU2020250613A1 (en) | 2021-11-11 |
CN113631582A (en) | 2021-11-09 |
WO2020200256A1 (en) | 2020-10-08 |
EP3950720A4 (en) | 2023-04-12 |
CA3131075A1 (en) | 2020-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL288373A (en) | Flt3l-fc fusion proteins and methods of use | |
IL279510A (en) | Progranulin-fc polypeptide fusion proteins and uses thereof | |
SG11202012004SA (en) | Rna-targeting fusion protein compositions and methods for use | |
IL267861A (en) | A pd1-41bbl fusion protein and methods of use thereof | |
IL280102A (en) | Pd1-4-1bbl variant fusion protein and methods of use thereof | |
IL267862A (en) | A sirpalpha-41bbl fusion protein and methods of use thereof | |
EP3960756A4 (en) | Flagellin fusion protein and use thereof | |
SG11202110400QA (en) | Fusion protein and use thereof | |
EP3722305A4 (en) | Hm-3 fusion protein and use thereof | |
IL284679A (en) | Multi-functional fusion proteins and uses thereof | |
SG11202104912SA (en) | Fusion protein and use thereof | |
IL280103A (en) | Sirpalpha-4-1bbl variant fusion protein and methods of use thereof | |
IL275248A (en) | Therapeutic enzyme fusion protein having a novel structure and use thereof | |
ZA202000595B (en) | Novel therapeutic enzyme fusion protein and use thereof | |
ZA202100092B (en) | Modified cas9 protein and use thereof | |
EP3858866A4 (en) | Glp1-fc fusion protein and conjugate thereof | |
IL279057A (en) | Endolysin-containing antimicrobial fusion proteins and uses thereof | |
IL290715A (en) | Nkg2d fusion proteins and uses thereof | |
EP3816181A4 (en) | Improved fviii fusion protein and use thereof | |
IL286799A (en) | Fusion constructs and uses thereof | |
GB202201004D0 (en) | Reconbinant fusion polypeptide and use thereof | |
GB202201003D0 (en) | Fusion polypeptide and use thereof | |
ZA202102533B (en) | Fusion protein | |
GB202201001D0 (en) | Polypeptide and use thereof | |
EP3976630A4 (en) | Actrii-binding proteins and uses thereof |